46 related articles for article (PubMed ID: 18470917)
21. Proteasome inhibition rescues clinically significant unstable variants of the mismatch repair protein Msh2.
Arlow T; Scott K; Wagenseller A; Gammie A
Proc Natl Acad Sci U S A; 2013 Jan; 110(1):246-51. PubMed ID: 23248292
[TBL] [Abstract][Full Text] [Related]
22. Massively parallel functional testing of MSH2 missense variants conferring Lynch syndrome risk.
Jia X; Burugula BB; Chen V; Lemons RM; Jayakody S; Maksutova M; Kitzman JO
Am J Hum Genet; 2021 Jan; 108(1):163-175. PubMed ID: 33357406
[TBL] [Abstract][Full Text] [Related]
23. Multiplexed assays reveal effects of missense variants in MSH2 and cancer predisposition.
Nielsen SV; Hartmann-Petersen R; Stein A; Lindorff-Larsen K
PLoS Genet; 2021 Apr; 17(4):e1009496. PubMed ID: 33886538
[No Abstract] [Full Text] [Related]
24. Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance.
Hofstra RM; Spurdle AB; Eccles D; Foulkes WD; de Wind N; Hoogerbrugge N; Hogervorst FB;
Hum Mutat; 2008 Nov; 29(11):1292-303. PubMed ID: 18951447
[TBL] [Abstract][Full Text] [Related]
25. Somatic polymerase epsilon mutations as another route leading to loss of DNA MMR protein expression in endometrial carcinoma.
Westenend PJ; Dinjens WN
Hum Pathol; 2018 Jun; 76():169. PubMed ID: 29634980
[No Abstract] [Full Text] [Related]
26. Multiplexing mutation rate assessment: determining pathogenicity of Msh2 variants in Saccharomyces cerevisiae.
Ollodart AR; Yeh CC; Miller AW; Shirts BH; Gordon AS; Dunham MJ
Genetics; 2021 Jun; 218(2):. PubMed ID: 33848333
[TBL] [Abstract][Full Text] [Related]
27. Structural debilitation of mutation G322D associated with MSH2 and their role in triple negative breast cancer.
Sriroopreddy R; Raghuraman P; Sudandiradoss C
J Biomol Struct Dyn; 2020 Feb; 38(3):771-780. PubMed ID: 30806579
[TBL] [Abstract][Full Text] [Related]
28. In-silico analysis of Thr767Ile pathogenic variant in the MSH6 gene in family with endometrial cancer.
Stembalska A; Klapecki J; Pławski A; Karpinski P
Eur J Obstet Gynecol Reprod Biol; 2019 Jul; 238():54-57. PubMed ID: 31100584
[TBL] [Abstract][Full Text] [Related]
29. Germline MLH1 and MSH2 mutations in Italian pancreatic cancer patients with suspected Lynch syndrome.
Gargiulo S; Torrini M; Ollila S; Nasti S; Pastorino L; Cusano R; Bonelli L; Battistuzzi L; Mastracci L; Bruno W; Savarino V; Sciallero S; Borgonovo G; Nyström M; Bianchi-Scarrà G; Mareni C; Ghiorzo P
Fam Cancer; 2009; 8(4):547-53. PubMed ID: 19728162
[TBL] [Abstract][Full Text] [Related]
30. Do non-pathogenic variants of DNA mismatch repair genes modify neurofibroma load in neurofibromatosis type 1?
Harder A
Childs Nerv Syst; 2022 Apr; 38(4):705-713. PubMed ID: 34997843
[TBL] [Abstract][Full Text] [Related]
31. Functional interrogation of Lynch syndrome-associated MSH2 missense variants via CRISPR-Cas9 gene editing in human embryonic stem cells.
Rath A; Mishra A; Ferreira VD; Hu C; Omerza G; Kelly K; Hesse A; Reddi HV; Grady JP; Heinen CD
Hum Mutat; 2019 Nov; 40(11):2044-2056. PubMed ID: 31237724
[TBL] [Abstract][Full Text] [Related]
32. Mismatch repair analysis of inherited MSH2 and/or MSH6 variation pairs found in cancer patients.
Kantelinen J; Kansikas M; Candelin S; Hampel H; Smith B; Holm L; Kariola R; Nyström M
Hum Mutat; 2012 Aug; 33(8):1294-301. PubMed ID: 22581703
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of pathogenicity in human MSH2 missense mutants.
Ollila S; Dermadi Bebek D; Jiricny J; Nyström M
Hum Mutat; 2008 Nov; 29(11):1355-63. PubMed ID: 18951462
[TBL] [Abstract][Full Text] [Related]
34. Functional analysis of HNPCC-related missense mutations in MSH2.
Lützen A; de Wind N; Georgijevic D; Nielsen FC; Rasmussen LJ
Mutat Res; 2008 Oct; 645(1-2):44-55. PubMed ID: 18822302
[TBL] [Abstract][Full Text] [Related]
35. Two mismatch repair gene mutations found in a colon cancer patient--which one is pathogenic?
Kariola R; Otway R; Lönnqvist KE; Raevaara TE; Macrae F; Vos YJ; Kohonen-Corish M; Hofstra RM; Nyström-Lahti M
Hum Genet; 2003 Feb; 112(2):105-9. PubMed ID: 12522549
[TBL] [Abstract][Full Text] [Related]
36. Functional analysis of MSH2 unclassified variants found in suspected Lynch syndrome patients reveals pathogenicity due to attenuated mismatch repair.
Wielders EA; Hettinger J; Dekker R; Kets CM; Ligtenberg MJ; Mensenkamp AR; van den Ouweland AM; Prins J; Wagner A; Dinjens WN; Dubbink HJ; van Hest LP; Menko F; Hogervorst F; Verhoef S; te Riele H
J Med Genet; 2014 Apr; 51(4):245-53. PubMed ID: 24501230
[TBL] [Abstract][Full Text] [Related]
37. A rapid and cell-free assay to test the activity of lynch syndrome-associated MSH2 and MSH6 missense variants.
Drost M; Zonneveld JB; van Hees S; Rasmussen LJ; Hofstra RM; de Wind N
Hum Mutat; 2012 Mar; 33(3):488-94. PubMed ID: 22102614
[TBL] [Abstract][Full Text] [Related]
38. Uncertain pathogenicity of MSH2 variants N127S and G322D challenges their classification.
Ollila S; Dermadi Bebek D; Greenblatt M; Nyström M
Int J Cancer; 2008 Aug; 123(3):720-4. PubMed ID: 18470917
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
